RBC Capital analyst Gregory Renza reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $8 price target.
EXCLUSIVE: Ocean Biomedical Highlights New Results From Anti-Cancer Antibody Validating Tumor Suppression In Animal Models With Brain Tumor
Ocean Biomedical Inc's (NASDAQ: OCEA) co-founder, Jack Elias, published new findings in the peer-reviewed journal Cancer Research detailing the mechanisms behind the role of chitinase 3-like-1 (Chi3L1) in the growth of glioblastoma tumors.
